Health care
OwnerAnthony I. Rozmanith, Jolan S. Rozmanithinventors
Life of this patent
Estimating the term…
Abstract
The treatment of Type 2 diabetes involving the use of a regimen comprising: (A) one or more glucose-lowering drugs (G-LDs) which function to lower the amount of glucose in the blood, preferably glyburide and metformin; (B) at least one non-steroidal anti-inflammatory drug (NSAID) selected from the group consisting of (1) magnesium salicylate tetrahydrate (hereafter “Mg salicylate”); (2) naproxen; and (3) ibuprofen; and (C) acetaminophen. Also, a regimen for use in deterring the development in an individual of a cardiovascular disease or of Alzheimer's and/or for treating individuals who are affected with such diseases, the regimen comprising aforementioned ingredients (B) and (C) above.
Claims20
A method for treating an individual comprising the use by the individual of a regimen which includes the ingestion daily by the individual of a pharmaceutically effective amount of:
- (A) one or more glucose-lowering drugs (G-LDs) which function to lower the amount of glucose in the blood;
- (B) at least one non-steroidal anti-inflammatory drug (NSAID) selected from the group consisting of (1) magnesium salicylate tetrahydrate (hereafter “Mg salicylate”);
- (2) naproxen;
- and (3) ibuprofen;
- and
- (C) acetaminophen.
A method for use in deterring the development in an individual of a cardiovascular disease or of Alzheimer's and/or for treating an individual who is effected with one or more of such diseases comprising the ingestion by the individual on a daily basis of:
- (A) at least one non-steroidal anti-inflammatory drug (NSAID) selected from the group consisting of magnesium salicylate tetrahydrate (hereafter Mg salicylate, naproxen, and ibuprofen;
- and
- (B) acetaminophen.
A regimen comprising multi-ingredients which are associated with each other for use in treating on a daily basis an individual in order to prevent or to delay the onset of Type 2 diabetes in which the regimen comprises in pharmaceutically effective amounts:
- (A) one or more glucose-lowering drugs (G-LDs) which function to lower the amount of glucose in the blood;
- (B) at least one non-steroidal anti-inflammatory drug (NSAID) selected from the group consisting of (1) magnesium salicylate tetrahydrate (hereafter “Mg salicylate”);
- (2) naproxen;
- and (3) ibuprofen;
- and
- (C) acetaminophen.
Dependencies are inferred from the claim text.